We are proud to announce the successful sale of our portfolio company Kappa Bioscience to Balchem Corporation (NASDAQ: BCPC). We invested in Kappa, a manufacturer of vitamin K2, in 2019 alongside our Nordic investment partner Verdane and watched as the company subsequently quadrupled EBITDA during our ownership period. We are thrilled by what the teams at Kappa and Verdane have achieved during our partnership. Growing the business with high quality and pace, expanding geographical footprint and constructing a new advanced manufacturing facility were no easy feats. We are confident that Balchem is a great strategic fit for Kappa and are looking forward to their joint successes.

Read more about this successful transaction for ALP here.